Apr. 19 at 10:23 PM
$XENE - Groundbreaking Seizure Reduction Data
👉Click to view @NasdaqPulse for timely updates amid the volatility.
Exciting news from
$XENE with Azetukalner showing significant reductions in seizure frequency across various time points, including weekly, monthly, and multi-year data.
Key highlights:
X-TOLE2 Data: 53.2% reduction in monthly seizure frequency in the 25 mg group vs. just 10.4% for placebo, with increasing rates of 100% seizure reduction during the 12-week period!
Long-term X-TOLE OLE Study: After 48 months, nearly 40% of participants achieved at least 12 months seizure-free, and 1 in 4 saw 24+ months seizure freedom.
Real-World Data: Anti-seizure meds that don’t require titration are proving to reduce stress and simplify treatment for both patients and doctors.
Big potential for
$XENE in the seizure management space—this could be a game-changer!
